Heart failure is not just a diagnosis — it is a daily struggle. Breathlessness at rest, swollen feet, disrupted sleep, and repeated hospital visits slowly rob patients of their independence. If your cardiologist has prescribed Sacubitril 49mg Valsartan 51mg tablet, you are now on one of the most clinically validated treatment pathways available today for chronic heart failure.

This page gives you everything you need to know — mechanism of action, dosage, precautions, and what to expect — so that you and your caregiver can make informed, confident decisions.

What Is Sacubitril 49mg Valsartan 51mg Tablet?

Sacubitril and Valsartan is a combination medicine used in adults with chronic heart failure. It lowers the risk of being hospitalized when symptoms worsen and reduces the risk of death from heart failure.

It is a combination of Sacubitril, a neprilysin inhibitor, and Valsartan, an angiotensin II receptor blocker (ARB), indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. 

This tablet is commonly known by the brand name Entresto globally and is available as a fixed-dose combination (FDC) film-coated tablet. The 49mg/51mg strength is sometimes referred to as the "100 mg" dose, representing the combined sum of both active ingredients. 

How Does This Combination Work? (Dual Mechanism of Action)

The therapeutic power of this tablet lies in its two-pronged cardiovascular approach:

Sacubitril 49mg — Neprilysin Inhibitor
Sacubitril is converted in the body to LBQ657, which inhibits neprilysin — an enzyme that breaks down beneficial natriuretic peptides. By blocking this enzyme, the body retains natural substances that promote vasodilation, reduce sodium retention, and decrease cardiac fibrosis. The net result is a heart that pumps more efficiently with less strain.

Valsartan 51mg — Angiotensin II Receptor Blocker (ARB)
Valsartan blocks the angiotensin II receptor, preventing the harmful vasoconstriction and aldosterone release that raises blood pressure and worsens heart failure. It directly reduces the workload on the left ventricle.

Together, these two molecules address the neurohormonal overactivation that drives heart failure progression — making this combination superior to either agent alone.

Approved Indications

Sacubitril and Valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. 

It is also used to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. 

Dosage & How to Take

The initial recommended dose is Sacubitril 49mg–Valsartan 51mg orally twice a day. The target maintenance dose is Sacubitril 97mg–Valsartan 103mg orally twice a day. The dose is increased to the target maintenance level after 2 to 4 weeks, as tolerated by the patient. 

Sacubitril and Valsartan is usually taken twice per day, with or without food. Patients may need to take more than one tablet to receive a full dose, and should follow their doctor's instructions carefully. 

Special Population Dosing:

For patients not currently taking an ACE inhibitor or ARB, or those previously taking low doses of these agents, treatment should be started at half the normally recommended initial dose, with subsequent titration as per the recommended escalation schedule. 

For patients with severe renal impairment (eGFR less than 30 mL/min/1.73m²), the starting dose should be reduced to 24mg/26mg twice daily, with dose doubling every 2 to 4 weeks toward the target maintenance dose, as tolerated. 

Important Precautions & Warnings

Patient safety always comes first. Please review these precautions carefully before starting therapy:

ACE Inhibitor Interaction: This medicine is contraindicated with concomitant use of an ACE inhibitor. If switching from an ACE inhibitor, a washout period of 36 hours must be observed between the two drugs.

Pregnancy: This medicine must not be used during pregnancy. It can cause fetal harm and is absolutely contraindicated during all trimesters. 

Blood Pressure Monitoring: Sacubitril/Valsartan lowers blood pressure and may cause symptomatic hypotension. Patients who are volume-depleted or salt-depleted, or those already taking diuretics, are at greater risk. 

Potassium Levels: Avoid potassium supplements and potassium-rich foods such as bananas and broccoli while on this medicine, as it may raise blood potassium levels. 

Kidney & Liver Disease: Inform your doctor if you have a history of liver or kidney disease before starting treatment.

Common Side Effects

The most commonly reported side effects include low blood pressure (hypotension), dizziness, cough, increased potassium levels in the blood, and elevated creatinine levels. 

Serious symptoms requiring immediate medical attention include signs of high blood potassium such as nausea, weakness, tingling sensations, chest pain, or irregular heartbeat, as well as signs of kidney problems such as swelling, reduced urination, or unusual fatigue. 

Angioedema (swelling of the face, lips, or throat) is a rare but serious adverse reaction. Seek emergency care if this occurs.

Why This Tablet Is a Cardiologist's First Choice

The Sacubitril/Valsartan combination has demonstrated superiority over standard heart failure therapy in landmark clinical trials. Its dual action significantly reduces both all-cause mortality and heart failure hospitalizations. It also reduces NT-proBNP — a key biomarker of cardiac stress — and is expected to improve cardiovascular outcomes broadly.

For patients on chronic heart failure therapy looking for a step up in cardiac protection, this tablet represents a meaningful, evidence-backed upgrade.

Frequently Asked Questions

Q1. What is Sacubitril 49mg Valsartan 51mg tablet used for?
It is used to treat chronic heart failure in adults, specifically to reduce the risk of cardiovascular death and hospitalization. It is also approved for use in children aged one year and above with symptomatic heart failure.

Q2. How should I take Sacubitril 49mg Valsartan 51mg tablet?
Take one tablet twice daily, with or without food. Your doctor will start you at this dose and may increase it to the higher strength (97mg/103mg) after 2 to 4 weeks, depending on how well you tolerate the medicine.

Q3. Can I take Sacubitril Valsartan with my ACE inhibitor?
No. These two must never be taken together. A mandatory gap of 36 hours is required if you are switching from an ACE inhibitor to Sacubitril/Valsartan. Always consult your cardiologist before making any changes.

Q4. What are the side effects of Sacubitril 49mg Valsartan 51mg?
Common side effects include dizziness, low blood pressure, cough, and elevated potassium. Rare but serious reactions include angioedema (facial or throat swelling), kidney problems, and dangerously high potassium levels. Seek immediate medical care for serious symptoms.

Q5. Is Sacubitril Valsartan safe during pregnancy?
No. This medicine is strictly contraindicated during pregnancy as it can harm the developing fetus. Women who are pregnant, planning to conceive, or breastfeeding must not use this medicine.

Q6. What is the difference between Sacubitril Valsartan 49/51mg and 97/103mg?
The 49mg/51mg tablet is the standard starting dose for most adults. After 2 to 4 weeks of tolerance, the dose is doubled to 97mg/103mg — the target maintenance dose for long-term heart failure management.

Q7. Can patients with kidney disease take this tablet?
Patients with mild to moderate kidney disease (eGFR ≥30) can take the standard starting dose. Those with severe kidney impairment should begin at a lower dose of 24mg/26mg, with careful dose titration under medical supervision.

Q8. How long does it take for Sacubitril Valsartan to show results?
Clinical improvements in symptoms and exercise tolerance may begin within a few weeks. However, the full cardiovascular protective benefits — including reduced hospitalizations and mortality — are observed over months of consistent use.

Brand Name: SACUBRIGHT 100 (STERIS HEALTHCARE PVT LTD)

Composition Name: Sacubitril 49 mg + Valsartan 51 mg

Formulation: Film-coated tablet

Pack Size: 1 x 14 Tablets

Marketed By: Steris Healthcare Pvt Ltd

Regulatory Standard: WHO-GMP Certified

Schedule: Valid Prescription Required (Prescription Only)

If You Need More Information About SACUBRIGHT 100 Click here